An Oral Formulation of the Probiotic, <i>Bacillus subtilis</i> HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy

<div>Changes in blood ammonia levels (a) by treatment group and (b) for patients stratified by baseline blood ammonia level; placebo group: <i>n</i> = 10, probiotic group: <i>n</i> = 28 (ammonia data were missing for 1 patient in each group); ns = not significant;<sup>∗ ∗</sup><i>p</i> ≤ 0.01.</div>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: An Oral Formulation of the Probiotic, <i>Bacillus subtilis</i> HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy 

Figure 3 | An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy 